RxDoctor Payments Data

Chemanoor Zachariah, MD

Internal Medicine · Tracy, CANPI 1780655951

Payments from drug & device makers

$2,568in general payments, 2019–2025

Across 169 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$659
  • Novo Nordisk$460
  • AbbVie$401
  • Amgen$288
  • Lilly USA, LLC$149
  • Sanofi-aventis U.S. LLC$148
  • plus $463 from 9 others

What the payments were for

  • Food & beverage$2,54899%
  • Other$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,568 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$113,130
Medicare patients
121
Services billed
915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$66,259
JardianceEmpagliflozin30$31,408
Synjardy XrEmpagliflozin/Metformin Hcl24$25,717
Soliqua 100-33Insulin Glargine/Lixisenatide18$22,364
Tresiba Flextouch U-200Insulin Degludec20$22,220
TrulicityDulaglutide13$20,323
Repatha SureclickEvolocumab22$19,751
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$18,494
EliquisApixaban22$17,402
Tresiba Flextouch U-100Insulin Degludec11$17,202
LinzessLinaclotide18$13,882
JanuviaSitagliptin Phosphate24$12,315
SynjardyEmpagliflozin/Metformin Hcl12$10,274
Praluent PenAlirocumab12$9,602
Saxagliptin Hcl11$3,671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$49$67,39966 claims
Novo NordiskOzempic$460$66,25964 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$148$22,36418 claims
Lilly USA, LLCTrulicity$149$20,32313 claims
AstraZenecaBreztri Aerosphere$659$18,49425 claims
PfizerEliquis$96$17,40222 claims
AbbVieLinzess$401$13,88218 claims
MerckJanuvia$14$12,31524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Tracy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →